Gooderham, Melinda J.
de Bruin-Weller, Marjolein
Weidinger, Stephan
Cork, Michael J.
Eichenfield, Lawrence F.
Simpson, Eric L.
Tsianakas, Athanasios
Kerkmann, Urs
Feeney, Claire
Romero, William
Funding for this research was provided by:
Pfizer Inc
Article History
Received: 6 March 2024
Accepted: 30 May 2024
First Online: 2 July 2024
Declarations
:
: Melinda J. Gooderham has received grants, personal fees, honoraria, and/or nonfinancial support from Pfizer Inc., AbbVie, Amgen, Akros Pharma, Arcutis, AnaptysBio, Aristea, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, InMagene, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Moonlake, Meiji, Novartis, Roche, Sanofi Genzyme, Regeneron Pharmaceuticals, Sun Pharma, Takeda, Tarsus, UCB, Union and Ventyx. Marjolein de Bruin-Weller is a consultant, advisory board member, and/or speaker for Pfizer Inc., AbbVie, Almirall, Arena, Aslan, Eli Lilly and Company, Galderma, Janssen, LEO Pharma, Regeneron Pharmaceuticals, and Sanofi Genzyme. Stephan Weidinger has received institutional research grants from Pfizer Inc., La Roche-Posay, LEO Pharma, and Sanofi Deutschland GmbH; has performed consultancies for Pfizer Inc., AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly and Company, Galderma, Kymab, LEO Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; has lectured at educational events sponsored by Pfizer Inc., AbbVie, Almirall, Galderma, LEO Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Michael J. Cork has been a clinical trial investigator for Pfizer Inc., Atopix, Galapagos, Hyphens, Johnson & Johnson, Kymab, LEO Pharma, L’Oreal/La Roche-Posay, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; and an advisory board member, consultant, and/or invited lecturer for Pfizer Inc., Abbvie, Amlar, Astellas, Atopix, Boots, Dermavant, Galapagos, Galderma, Hyphens, Johnson & Johnson, Kymab, LEO Pharma, L’Oreal/La Roche-Posay, Menlo Therapeutics, Novartis, Oxagen, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals, and Sanofi Genzyme. Lawrence F. Eichenfield has served as a scientific adviser, consultant, and/or clinical study investigator for Pfizer Inc., AbbVie, Amgen, Apogee, Arcutis, Aslan, Attovia, Bristol Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly and Company, Forte, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Regeneron Pharmaceuticals, Sanofi Genzyme, Target RWE and UCB. Eric L. Simpson has received grants from Pfizer Inc., Eli Lilly and Company, Kyowa Kirin, LEO Pharma, Merck, and Regeneron Pharmaceuticals, and personal fees from Pfizer Inc., Bausch Health (Valeant), Dermira, Eli Lilly and Company, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme. Athanasios Tsianakas has acted as a clinical investigator and received honoraria for lectures and consulting from Pfizer Inc. Claire Feeney is an employee and shareholder of Pfizer Inc. Urs Kerkmann was an employee and shareholder of Pfizer Pharma GmbH at the time the study was conducted. William Romero was an employee and shareholder of Pfizer Inc. at the time the study was conducted. He is currently an employee of Eli Lilly and Company Limited.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.